A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-08Estimated
Enrollment · participants12Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.